| Molecular Partners ： ウィキペディア英語版|
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zurich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins,〔Plückthun A (2015). "(Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy )". Annu. Rev. Pharmacol. Toxicol. 55: 489-511. . PMID 25562645.〕〔Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A (2003)."(Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins )". J. Mol. Biol. 332 (2): 489–503. . PMID 12948497.〕 with potential clinical applications in a range of disease areas including ophthalmology, oncology and immunology. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.〔(Molecular Partners AG Annual Report 2014 ) (PDF). March 2015.〕
== History ==
Researchers at the University of Zurich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.〔〔
Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange.〔(Initial public offering markets reopen to European biopharmaceutical firms )". BioWorld. January 5, 2015.〕〔"(Molecular Partners Rises in Trading Debut on Allergan Support )". FirstWordPharma. November 5, 2014.〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
| 翻訳と辞書 : 翻訳のためのインターネットリソース|
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.